This upside in RNA stock is being driven by the encouraging clinical development of its three rare neuromuscular programs — ...

People with Myotonic Dystrophy Type 1 (DM1), the most common adult-onset form of muscular dystrophy, progressively lose muscle mass and strength in their lower legs, hands, neck and face. The effects ...

US FDA grants rare paediatric designation to ARTHEx Biotech’s ATX-01 for the treatment of myotonic dystrophy type 1: Valencia, Spain Friday, November 8, 2024, 16:00 Hrs [IST] AR ...

Avidity Biosciences (NASDAQ:RNA) has surged ~16% Wednesday, reaching an all-time high of $56.00 earlier in the trading ...

Investors consider Dyne Therapeutics' treatments for muscle diseases and strong cash position as a speculative Buy ...

A new mouse model mimicking the liver symptoms of myotonic dystrophy type 1—the most prevalent form of adult-onset muscular dystrophy—provides insight into why patients develop fatty liver ...

According to the Mayo Clinic, muscular dystrophy is a group of diseases that cause loss of muscle mass and progressive ...

Analyst Michael Ulz from Morgan Stanley reiterated a Buy rating on Dyne Therapeutics (DYN – Research Report) and keeping the price target ...

Dyne Therapeutics, Inc. ( (DYN) ) has released its Q3 earnings. Here is a breakdown of the information Dyne Therapeutics, Inc. presented to its ...

Detailed price information for Design Therapeutics Inc (DSGN-Q) from The Globe and Mail including charting and trades.